Bridge Biotherapeutics (Korea) Top Management
| 288330 Stock | KRW 4,050 445.00 9.90% |
Bridge Biotherapeutics employs about 4 people. The company is managed by 4 executives with a total tenure of roughly 10 years, averaging almost 2.0 years of service per executive, having 1.0 employees per reported executive. Analysis of Bridge Biotherapeutics' management performance can provide insight into the company performance.
| Taeksang Park Insider VP CFO |
| Gwanghee Lee Insider VP Director |
Bridge |
Bridge Biotherapeutics Management Team Effectiveness
Bridge Biotherapeutics' management efficiency ratios could be used to measure how well Bridge Biotherapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Bridge Biotherapeutics Workforce Comparison
Bridge Biotherapeutics is rated fourth in number of employees category among its peers. The total workforce of Biotechnology & Medical Research industry is presently estimated at about 182. Bridge Biotherapeutics holds roughly 4.0 in number of employees claiming about 2.2% of stocks in Biotechnology & Medical Research industry.
Bridge Biotherapeutics Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Bridge Biotherapeutics Price Series Summation is a cross summation of Bridge Biotherapeutics price series and its benchmark/peer.
Bridge Biotherapeutics Notable Stakeholders
A Bridge Biotherapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Bridge Biotherapeutics often face trade-offs trying to please all of them. Bridge Biotherapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Bridge Biotherapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Taeksang Park | VP CFO | Profile | |
| Gwanghee Lee | VP Director | Profile | |
| SangUk Kang | VP Director | Profile | |
| James Lee | CEO Director | Profile |
About Bridge Biotherapeutics Management Performance
The success or failure of an entity such as Bridge Biotherapeutics often depends on how effective the management is. Bridge Biotherapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Bridge management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Bridge management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Bridge Biotherapeutics, Inc., a clinical stage biotech company, engages in the development of therapeutics for the treatment of ulcerative colitis, fibrotic diseases, and cancers worldwide. The company was founded in 2015 and is headquartered in Seongnam, Korea. BRIDGE BIOTHERAPEUTICS is traded on Korean Securities Dealers Automated Quotations in South Korea.
Please note, the presentation of Bridge Biotherapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Bridge Biotherapeutics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Bridge Biotherapeutics' management manipulating its earnings.
Bridge Biotherapeutics Workforce Analysis
Traditionally, organizations such as Bridge Biotherapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Bridge Biotherapeutics within its industry.Bridge Biotherapeutics Manpower Efficiency
Return on Bridge Biotherapeutics Manpower
| Revenue Per Employee | 481M | |
| Revenue Per Executive | 481M | |
| Net Loss Per Employee | 6.6B | |
| Net Loss Per Executive | 6.6B |
Complementary Tools for Bridge Stock analysis
When running Bridge Biotherapeutics' price analysis, check to measure Bridge Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bridge Biotherapeutics is operating at the current time. Most of Bridge Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Bridge Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bridge Biotherapeutics' price. Additionally, you may evaluate how the addition of Bridge Biotherapeutics to your portfolios can decrease your overall portfolio volatility.
| Transaction History View history of all your transactions and understand their impact on performance | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules |